Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desvenlafaxine succinate
Drug ID BADD_D00622
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D02570; D11619
MeSH ID D000069468
PubChem ID 9800068
TTD Drug ID D0O3FG
NDC Product Code 16436-0087; 59762-1211; 63629-7559; 68180-593; 68180-604; 68788-7175; 71335-2130; 46708-541; 71335-1331; 59762-1222; 71205-586; 24196-162; 66651-928; 71335-1150; 72189-147; 42816-1211; 46708-542; 0008-1211; 68788-7194; 14501-0065; 42816-1210; 42816-1222; 65841-173; 68724-1236; 69766-008; 0008-1210; 51991-006; 68071-2704; 68180-592; 65977-0142; 0008-1222; 46708-540; 51991-312; 59762-1210; 63629-7525; 53296-0087; 50090-5274; 14778-0606; 51991-311
UNII ZB22ENF0XR
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C20H31NO6
CAS Registry Number 448904-47-0
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anorgasmia19.08.01.001--
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood prolactin increased13.10.03.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Constipation07.02.02.001--
Coronary artery occlusion12.02.01.036; 24.04.04.013; 02.02.01.006--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.014--Not Available
Diarrhoea07.02.01.001--
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Ejaculation delayed21.03.01.001--Not Available
Ejaculation disorder21.03.01.002--
Ejaculation failure21.03.01.003--Not Available
Epistaxis22.04.03.001; 24.07.01.005--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling jittery08.01.09.016--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypomania19.16.02.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
The 1th Page    1 2 3    Next   Last    Total 3 Pages